Navigation Links
Masimo Initiates Full Market Release of First-Ever Noninvasive Continuous Hemoglobin Monitor
Date:3/24/2009

making, improve care, and reduce costs."

SpHb has received regulatory clearance in the U.S., Canada, Europe and Australia, and is now available for sale in most of the countries in the world.

About Masimo

Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low-Perfusion pulse oximetry, known as Masimo SET(R), which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable Sp02 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET(R) Pulse CO-OximetryTM, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHbTM), oxygen content (SpOCTM), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVITM, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.

Forward Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Se
'/>"/>

SOURCE Masimo
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
2. AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in Improving Patient Outcomes and Reducing Costs in Post-Acute Care Facilities
3. Masimo Reports Third Quarter 2008 Financial Results
4. New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence
5. Five New Clinical Studies Show Value of Masimo PVI & PI
6. Masimo to Report Third Quarter 2008 Financial Results on October 27, 2008
7. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
8. Masimo Announces Desaturation Index 3D Alarm as Standard Feature in All Radical-7 Pulse CO-Oximetry Devices
9. Masimo to Present at Goldman Sachs 29th Annual Global Healthcare Conference
10. Masimo to Present at Deutsche Bank 33rd Annual Health Care Conference
11. Masimo Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Ore. , July 22, 2014  Semler ... an emerging medical risk assessment company that develops ... patients and evaluating chronic diseases, today announced that ... before the open of U.S. financial markets on July ... Semler will host a conference call at 11 a.m. ...
(Date:7/22/2014)... 2014 Holomic is expanding its ... of its fluorescent immunoassay reader, the HRDR-300, at ... in Chicago, July 28-31, 2014. Available in both ... HRDR-300 is a highly sensitive, low-cost fluorescent reader ... lateral flow immunoassays with high sensitivity and accuracy. ...
(Date:7/22/2014)... Dr. Williams says, “Bush has joined the constantly ... greatest health care system in the world is too ... trying to serve the public. Unfortunately, Bush has also ... enormous system that none of them can first describe ... of Open Letters ( http://is.gd/wdU2CM ) provides a critique ...
(Date:7/21/2014)... College of Arts and Sciences has received a ... nanoparticles. , Mathew M. Maye, associate professor of ... from the National Science Foundation (NSF). The award ... nanostructures, the results of which may impact gas ... , Maye,s approach is novel, in that ...
Breaking Biology Technology:Semler to Report Second Quarter 2014 Financial Results and Host Conference Call on July 25, 2014 2Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2Syracuse University chemist to use NSF grant to study materials chemistry, nanoscience 2
... , , ROCKVILLE, Md., July 21 ... appointment of John J. Trizzino as Senior Vice President, International ... Trizzino will report directly to Dr. Rahul Singhvi, Novavax,s President ... managing the company,s international alliances with pharmaceutical companies and all ...
... ... is pleased the U.S. Environmental Protection Agency will allow farmers the ability to improve upon ... for SmartStax, an insect-protection and weed control platform in corn, to 5 percent in the ... ...
... , , NEWARK, N.J., July 21 ... a specialty chemical technology based Life Science Company announced ... protocol testing, BioNeutral,s Ygiene(TM) Hospital Grade Antimicrobial passed the ... all 5.4 million spores of Clostridium difficile ...
Cached Biology Technology:Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances 2EPA Refuge Determination Positive for the Environment 2BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 2BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 3
(Date:7/22/2014)... team from the National Institute of Standards and ... demonstrated a dramatically improved technique for analyzing biological ... "signatures." The new NIST technique is an advanced ... but one that delivers signals that are 10,000 ... and 100 times stronger than obtained from comparable ...
(Date:7/22/2014)... reputation as disease causing agents, some viruses can ... to shape the world we live in today, ... Academy of Microbiology. , "Viruses participate in essential ... the planet, from contributing to biogeochemical cycles, shaping ... states Marilyn Roossinck of Pennsylvania State University, a ...
(Date:7/22/2014)... promise for treating damaged organs and tissues, but with ... their effectiveness. New methods are being developed and tested ... after transplantation, as described in a Review article in ... Mary Ann Liebert, Inc., publishers. The article is available ... website . , In the article ,Preconditioning ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Report on viruses looks beyond disease 2
... Researchers speaking in the first plenary session of the ... (IAS 2011) have today offered insights into current and ... developments over the past two years are beginning ... policy. The presentations reflect the breadth of expertise ...
... trailing a long length of rope behind you is not ... to manoeuvre, and can get tangled up or stuck on ... apart during cell division. The chromosomes are pulled by their ... Just like climbers carry their rope coiled up, cells make ...
... PHILADELPHIA The use of trastuzumab, chemotherapy and ... improved survival from the time central nervous system metastases ... researcher Adam Brufsky, M.D., Ph.D., said, "We clearly now ... chemotherapy, even if cancer spreads to the brain." ...
Cached Biology News:Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy 2Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy 3Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy 4Keeping it together 2Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients 2